ClinicalTrials.gg
CompletedNCT04153565Updated Jul 17, 2025Results posted

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

A Phase 1 interventional study of Pembrolizumab and Pemetrexed in Mesothelioma, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Mesothelioma with a site in Japan — 1 open to participants now, 4 under way, 1 of them phase 3. Mesothelioma · Japan.

Enrollment
11th of 12
19 · median 182
Started
2019
the only one that year
Phase 1
7 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
Merck Sharp & Dohme LLC

Among the 12 studies in Mesothelioma with a site in Japan, this one is the 11th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 1, and was the 7th registered.

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 60 are open to participants now.

Browse Mesothelioma studies →

Open to participants now

1 of the 12 studies in Mesothelioma with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 47 Mesothelioma studies recruiting now, 32 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Mesothelioma with a site in Japan, or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-randomized, study of pembrolizumab in combination with cisplatin and pemetrexed in treatment of naïve participants with a histologically confirmed diagnosis of advanced/unresectable malignant pleural mesothelioma (MPM) in Japanese participants. This study will evaluate the safety, tolerability, and preliminary efficacy of pembrolizumab in combination with cisplatin and pemetrexed. The primary objective is to evaluate the safety and tolerability of treatment with pembrolizumab in combination with cisplatin and pemetrexed.

03

Conditions studied

  • Mesothelioma

Browse trials for

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed diagnosis of advanced/unresectable malignant pleural mesothelioma (MPM)
  • Have at least one , which is systemic therapy naïve, radiologically assessed by the local site investigator per modified (RECIST) using imaging scanned within 28 days prior to the first dose in this study
  • Has a performance status of 0 or 1 on the (ECOG) Performance Scale
  • Has a of at least 3 months
  • Demonstrate adequate organ function
  • Male participants are eligible to participate if they agree to remain abstinent or agree to use unless confirmed to be azoospermic
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, using contraceptives or is not a woman of child bearing potential ()

Exclusion criteria

Exclusion Criteria:

  • A who has a positive pregnancy test within 72 hours prior to treatment allocation
  • Has received prior therapy with an anti-programmed cell-death 1 (anti ), anti programmed cell-death ligand 1 (anti-PD-L1), or anti programmed cell-death ligand 2 (anti PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
  • Has previously received systemic anti-cancer therapy (including agents) for MPM
  • Participants who received (neo) adjuvant previously may be eligible, only if the last dose of chemotherapy was completed at least 6 months before registration. Such participants must have recovered from all adverse events (AEs) due to previous (neo) therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible
  • Received radiation therapy to the lung that is > 30 gray (Gy) within 6 months of the first dose of trial treatment
  • Completed palliative radiotherapy within 7 days of the first dose of trial treatment
  • Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis
  • Had a major surgery within 3 months prior to the first administration in this study
  • Has received a within 30 days prior to the first dose of study drug
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study drug
  • Has a known additional that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has had a severe reaction (≥Grade 3) to treatment a monoclonal antibody/components of the study intervention
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Is being treated for pericardial effusion, or has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions is eligible
  • Has an active infection requiring systemic therapy
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Cisplatin + Pemetrexed

    Pembrolizumab 200 mg IV every 3 weeks (Q3W) in combination with Cisplatin 75 mg/m\^2 IV, and Pemetrexed 500 mg/m\^2 IV for 4-6 cycles followed by monotherapy of Pembrolizumab up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years).

    Drug: Pembrolizumab · Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).

    Also known as: Keytruda, MK-3475

  • Participants will receive Pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks

    Also known as: Alimta

  • Participants will receive Cisplatin 75 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks

    Also known as: Platinol-AQ

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE)

    DLTs were assessed during Cycle 1 (21 days) and defined as any of the following, if considered by investigator to be related to any of the study interventions: Grade 4 hematologic toxicities, except neutropenia and febrile neutropenia; Grade 4 neutropenia lasting \>7 days despite appropriate supportive treatment; Grade 4 febrile neutropenia only if the event considered as clinically significant by investigator and sponsor; any Grade 4 non-hematologic toxicity (except laboratory test abnormal including transient electrolyte abnormalities); any Grade 3 non-hematologic toxicity lasting \>72 hours despite appropriate supportive treatment (not laboratory); and any Grade 4 laboratory test value abnormality; any Grade 3 laboratory test value abnormality lasting \>7 days; delay in start of second course of more than 2 weeks (more than 35 days after the first dose) due to toxicity related to study procedures; any Grade 5 toxicity.

    Time frame: Up to 3 weeks (through Cycle 1 [21 days])

  2. Number of Participants With One or More Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.

    Time frame: Up to approximately 34 months

  3. Number of Participants Discontinuing Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who have a Complete Response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions). ORR was based on modified Response Evaluation Criteria In Solid Tumors (RECIST) for Malignant Pleural Mesothelioma (MPM) as assessed by investigator.

    Time frame: Up to approximately 31 months

  2. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who had a Complete Response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD.\]) DCR was based on modified RECIST for MPM as assessed by investigator.

    Time frame: Up to approximately 31 months

  3. Duration of Response (DOR)

    For participants who demonstrate a confirmed complete response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or confirmed Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR was based on modified RECIST for MPM as assessed by investigator.

    Time frame: Up to approximately 31 months

07

Results

Posted Mar 22, 2024

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + Pemetrexed + Cisplatin
Started19
Completed6
Not completed13
Withdrew: Death13

Outcome measures

PrimaryNumber of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE)

DLTs were assessed during Cycle 1 (21 days) and defined as any of the following, if considered by investigator to be related to any of the study interventions: Grade 4 hematologic toxicities, except neutropenia and febrile neutropenia; Grade 4 neutropenia lasting \>7 days despite appropriate supportive treatment; Grade 4 febrile neutropenia only if the event considered as clinically significant by investigator and sponsor; any Grade 4 non-hematologic toxicity (except laboratory test abnormal including transient electrolyte abnormalities); any Grade 3 non-hematologic toxicity lasting \>72 hours despite appropriate supportive treatment (not laboratory); and any Grade 4 laboratory test value abnormality; any Grade 3 laboratory test value abnormality lasting \>7 days; delay in start of second course of more than 2 weeks (more than 35 days after the first dose) due to toxicity related to study procedures; any Grade 5 toxicity.

Time frame:
Up to 3 weeks (through Cycle 1 [21 days])
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE)
ParticipantsPembrolizumab + Pemetrexed + Cisplatin
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE)2
PrimaryNumber of Participants With One or More Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.

Time frame:
Up to approximately 34 months
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs)
ParticipantsPembrolizumab + Pemetrexed + Cisplatin
Number of Participants With One or More Adverse Events (AEs)19
PrimaryNumber of Participants Discontinuing Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.

Time frame:
Up to approximately 2 years
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Treatment Due to an AE
ParticipantsPembrolizumab + Pemetrexed + Cisplatin
Number of Participants Discontinuing Study Treatment Due to an AE6
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who have a Complete Response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions). ORR was based on modified Response Evaluation Criteria In Solid Tumors (RECIST) for Malignant Pleural Mesothelioma (MPM) as assessed by investigator.

Time frame:
Up to approximately 31 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPembrolizumab + Pemetrexed + Cisplatin
Objective Response Rate (ORR)73.7 (48.8 to 90.9)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants who had a Complete Response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD.\]) DCR was based on modified RECIST for MPM as assessed by investigator.

Time frame:
Up to approximately 31 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsPembrolizumab + Pemetrexed + Cisplatin
Disease Control Rate (DCR)94.7 (74.0 to 99.9)
SecondaryDuration of Response (DOR)

For participants who demonstrate a confirmed complete response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or confirmed Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR was based on modified RECIST for MPM as assessed by investigator.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab + Pemetrexed + Cisplatin
Duration of Response (DOR)16.8 (3.0 to NA)

Adverse events

Collected over Up to approximately 34 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Pemetrexed + Cisplatin13/19 (68.4%)7/19 (36.8%)19/19 (100%)
Most frequent serious events
Most frequent serious events
EventPembrolizumab + Pemetrexed + Cisplatin
PneumonitisRespiratory, thoracic and mediastinal disorders2/19
Pneumonia bacterialInfections and infestations2/19
Febrile neutropeniaBlood and lymphatic system disorders1/19
UveitisEye disorders1/19
PyrexiaGeneral disorders1/19
COVID-19Infections and infestations1/19
Facial paralysisNervous system disorders1/19
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPembrolizumab + Pemetrexed + Cisplatin
NauseaGastrointestinal disorders16/19
ConstipationGastrointestinal disorders13/19
AnaemiaBlood and lymphatic system disorders11/19
DiarrhoeaGastrointestinal disorders10/19
MalaiseGeneral disorders9/19
White blood cell count decreasedInvestigations7/19
DysgeusiaNervous system disorders7/19
NeutropeniaBlood and lymphatic system disorders6/19
RashSkin and subcutaneous tissue disorders6/19
Decreased appetiteMetabolism and nutrition disorders5/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + Pemetrexed + Cisplatin
Mean67.8 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Pemetrexed + Cisplatin
Female4
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Pemetrexed + Cisplatin
Hispanic or Latino0
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Pemetrexed + Cisplatin
American Indian or Alaska Native0
Asian19
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Hyogo College of Medicine Hospital ( Site 0003)
    Nishinomiya, Hyōgo 663-8501, Japan
  • Kanagawa Cancer Center ( Site 0004)
    Yokohama, Kanagawa 241-8515, Japan
  • JOHAS Okayama Rosai Hospital ( Site 0002)
    Okayama, 702-8055, Japan
  • National Cancer Center Hospital ( Site 0001)
    Tokyo, 104-0045, Japan
09

References and documents

Publications

  • Kijima T, Kato T, Goto Y, Kuribayashi K, Mikami K, Negi Y, Murakami S, Yoshida T, Homma M, Wakana A, Noguchi K, Fujimoto N. KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. Cancer Sci. 2025 Aug;116(8):2208-2217. doi: 10.1111/cas.70082. Epub 2025 May 23. PubMed 40407381 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Sep 2022, 33 months.

Results were first posted in Mar 2024, 1 year 6 months after primary completion.

Of 42 phase 1 interventional studies under Mesothelioma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 6, 2019
StartActual
Dec 9, 2019
Primary completionActual
Sep 21, 2022
CompletionActual
Sep 21, 2022
Results first posted
Mar 22, 2024
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04153565
Responsible party
Sponsor
First posted
Nov 6, 2019
Start date
Dec 9, 2019
Primary completion
Sep 21, 2022
Completion
Sep 21, 2022
Results posted
Mar 22, 2024
Last update
Jul 17, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion